Advanced search
Start date
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

learColi as a platform for untagged pneumococcal surface protein A production: cultivation strategy, bioreactor culture, and purificatio

Full text
Cardoso, Valdemir M. [1] ; Paredes, Sheyla A. H. [1] ; Campani, Gilson [2, 1] ; Goncalves, Viviane M. [3] ; Zangirolami, Teresa C. [1]
Total Authors: 5
[1] Fed Univ Sao Carlos UFSCar, Dept Chem Engn, Grad Program Chem Engn PPGEQ, Rodovia Washington Luis, Km 235, BR-13565905 Sao Carlos, SP - Brazil
[2] Univ Fed Lavras, Dept Engn, BR-37200900 Lavras, MG - Brazil
[3] Butantan Inst, Lab Vaccine Dev, Av Vital Brasil 1500, BR-05503900 Sao Paulo, SP - Brazil
Total Affiliations: 3
Document type: Journal article
Source: Applied Microbiology and Biotechnology; v. 106, n. 3, p. 1011-1029, FEB 2022.
Web of Science Citations: 0

Several studies have searched for new antigens to produce pneumococcal vaccines that are more effective and could provide broader coverage, given the great number of serotypes causing pneumococcal diseases. One of the promising subunit vaccine candidates is untagged recombinant pneumococcal surface protein A (PspA4Pro), obtainable in high quantities using recombinant Escherichia coli as a microbial factory. However, lipopolysaccharides (LPS) present in E. coli cell extracts must be removed, in order to obtain the target protein at the required purity, which makes the downstream process more complex and expensive. Endotoxin-free E. coli strains, which synthesize a nontoxic mutant LPS, may offer a cost-effective alternative way to produce recombinant proteins for application as therapeutics. This paper presents an investigation of PspA4Pro production employing the endotoxin-free recombinant strain ClearColi (R) BL21(DE3) with different media (defined, auto-induction, and other complex media), temperatures (27, 32, and 37 degrees C), and inducers. In comparison to conventional E. coli cells in a defined medium, ClearColi presented similar PspA4Pro yields, with lower productivities. Complex medium formulations supplemented with salts favored PspA4Pro yields, titers, and ClearColi growth rates. Induction with isopropyl-beta-D-thiogalactopyranoside (0.5 mM) and lactose (2.5 g/L) together in a defined medium at 32 degrees C, which appeared to be a promising cultivation strategy, was reproduced in 5 L bioreactor culture, leading to a yield of 146.0 mg PspA4Pro/g dry cell weight. After purification, the cell extract generated from ClearColi led to 98% purity PspA4Pro, which maintained secondary structure and biological function. ClearColi is a potential host for industrial recombinant protein production. (AU)

FAPESP's process: 16/50413-8 - Pulmonary delivery of a targeted mucosal nanocarrier vaccine for pneumonia
Grantee:Viviane Maimoni Gonçalves
Support Opportunities: Regular Research Grants
FAPESP's process: 15/10291-8 - Process intensification and integration for pneumococcal surface protein A production and purification
Grantee:Teresa Cristina Zangirolami
Support Opportunities: Regular Research Grants